Global Infantile Spasms Therapeutics Market 2017-2021

点頭てんかん治療薬の世界市場2017-2021

◆タイトル:Global Infantile Spasms Therapeutics Market 2017-2021
◆商品コード:IRTNTR11314
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年12月29日
◆ページ数:73
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、点頭てんかん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、点頭てんかん治療薬の世界市場規模及び予測、剤形別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・点頭てんかん治療薬の世界市場:市場概観
・点頭てんかん治療薬の世界市場:業界の構造分析
・点頭てんかん治療薬の世界市場:市場規模及び予測
・点頭てんかん治療薬の世界市場:剤形別分析
・点頭てんかん治療薬の世界市場:地域別分析
・点頭てんかん治療薬の世界市場:アジア市場規模
・点頭てんかん治療薬の世界市場:アメリカ市場規模
・点頭てんかん治療薬の世界市場:ヨーロッパ市場規模
・点頭てんかん治療薬の世界市場:成長要因
・点頭てんかん治療薬の世界市場:課題
・点頭てんかん治療薬の世界市場:市場動向
・点頭てんかん治療薬の世界市場:競争状況
・点頭てんかん治療薬の世界市場:主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Infantile Spasms Therapeutics
An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox–Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.

Technavio’s analysts forecast the global infantile spasms therapuetics market to grow at a CAGR of 10.16% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Infantile Spasms Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• H. Lundbeck
• Mallinckrodt Pharmaceuticals
• INSYS Therapeutics

[Other prominent vendors]
• Anavex Life Sciences
• Catalyst Pharmaceuticals
• GW Pharmaceuticals
• ORPHELIA Pharma
• Retrophin
• Valerion Therapeutics

[Market driver]
• Major drugs launch expected in 2017-2021
• For a full, detailed list, view our report

[Market challenge]
• Growing usage of seizure management devices, a threat to drug therapies
• For a full, detailed list, view our report

[Market trend]
• Development of devices and smartphone apps to detect seizures and track medications
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Infantile spasm: Overview

PART 06: Market landscape
• Global infantile spasms therapeutics market
• Five forces analysis

PART 07: Market segmentation by dosage form
• Solid
• Liquid

PART 08: Market segmentation by ROA
• Oral
• Parenteral

PART 09: Geographical segmentation
• Infantile spasms therapeutics market in Americas
• Infantile spasms therapeutics market in EMEA
• Infantile spasms therapeutics market in APAC

PART 10: Market drivers
• Major drugs launch expected in 2017-2021
• Growing scientific advancements in diagnostics
• Special regulatory designations

PART 11: Impact of drivers

PART 12: Market challenges
• Growing usage of seizure management devices, a threat to drug therapies
• Limited patient population
• Moderate pipeline

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Development of devices and smartphone apps to detect seizures and track medications
• Alternate drugs fill the gap
• Reformulation of marketed drugs

PART 15: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 16: Key vendor analysis
• H. Lundbeck
• Mallinckrodt Pharmaceuticals
• INSYS Therapeutics

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Snapshot of global infantile spasms therapeutics market 2016
Exhibit 03: Market overview of global infantile spasms therapeutics market
Exhibit 04: Opportunity analysis in developed and emerging markets
Exhibit 05: Global infantile spasm therapeutics market 2016-2021 ($ millions)
Exhibit 06: Approved infantile spasms therapeutics
Exhibit 07: Key customer segments of global infantile spasms therapeutics market
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global infantile spasms therapeutics market by dosage form
Exhibit 10: Segmentation of global infantile spasms therapeutics market by ROA
Exhibit 11: Market share of global infantile spasms therapeutics market by ROA
Exhibit 12: Snapshot of global infantile spasms therapeutics market by geography
Exhibit 13: Global infantile spasms therapeutics market segmentation by geography 2016-2021 ($ millions)
Exhibit 14: Overview of infantile spasms therapeutics disease market in Americas
Exhibit 15: Market scenario in Americas
Exhibit 16: Healthcare system in US: Before and after reforms in ACA
Exhibit 17: Orphan drug development and regulatory challenges in America
Exhibit 18: Incentives provided for orphan drugs by US regulation
Exhibit 19: Infantile spasms therapeutics disease market in Americas 2016-2021 ($ millions)
Exhibit 20: Overview of infantile spasms therapeutics market in EMEA
Exhibit 21: Percentage share of epilepsy drugs market in EMEA by geography 2015
Exhibit 22: Market scenario in EMEA
Exhibit 23: Incentives provided for orphan drugs by EU regulation
Exhibit 24: Infantile spasms therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 25: Overview of infantile spasms market in APAC
Exhibit 26: Market scenario in APAC
Exhibit 27: Incentives provided for orphan drugs by Japanese regulation
Exhibit 28: Incentives provided for orphan drugs by Australian regulation
Exhibit 29: Infantile spasms therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 30: CP-115 target indications
Exhibit 31: Clinical trial information for cannabidiol
Exhibit 32: Impact of drivers
Exhibit 33: Pipeline for infantile spasms therapeutics market
Exhibit 34: Pipeline molecules being developed for the treatment of infantile spasms disease
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Impact of trends in global infantile spasms therapeutics market
Exhibit 37: Competitive structure analysis of global infantile spasm therapeutics market 2016
Exhibit 38: Geographical presence of key vendors
Exhibit 39: H. Lundbeck: Key highlights
Exhibit 40: H. Lundbeck: Strength assessment
Exhibit 41: H. Lundbeck: Strategy assessment
Exhibit 42: H. Lundbeck: Opportunity assessment
Exhibit 43: Mallinckrodt Pharmaceuticals: Profile
Exhibit 44: Mallinckrodt Pharmaceuticals: Strength assessment
Exhibit 45: Mallinckrodt Pharmaceuticals: Strategy assessment
Exhibit 46: Mallinckrodt Pharmaceuticals: Opportunity assessment
Exhibit 47: INSYS Therapeutics: Key highlights
Exhibit 48: INSYS Therapeutics: Strength assessment
Exhibit 49: INSYS Therapeutics: Strategy assessment
Exhibit 50: INSYS Therapeutics: Opportunity assessment



【掲載企業】

H. Lundbeck, Mallinckrodt Pharmaceuticals, INSYS Therapeutics, Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, Valerion Therapeutics.

【資料のキーワード】

点頭てんかん、点頭てんかん治療薬、医療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[点頭てんかん治療薬の世界市場2017-2021]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆